Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study
Conclusion of the Authors: ROCA-based screening is an option for women at high risk of ovarian cancer/fallopian tube cancer who defer or decline risk reducing salpingo-oophorectomy, given its high sensitivity and significant stage shift. However, it remains unknown whether this strategy would improve survival in screened high-risk women.Read More
Performance characteristics and stage distribution of invasive epithelial ovarian/tubal/peritoneal cancers in UKCTOCS.
Postmenopausal women aged 50-74 were randomised (1:1:2 ratio) to annual multimodal (MMS) using the Risk of Ovarian Cancer Algorithm (ROCA) or ultrasound (USS) screening, or no screening (control, C). Women with abnormal screens had repeat tests and those with persistent abnormality underwent clinical evaluation and, where appropriate, surgery.Read More
Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial
Ovarian cancer has a poor prognosis, with just 40% of patients surviving 5 years. We designed this trial to establish the effect of early detection by screening on ovarian cancer mortality.Read More
UKCTOCS reports its first mortality analysis, potential for long term clinical benefit.
Data published in The Lancet today by one of the largest ever randomized trials has concluded that ovarian cancer screening may reduce ovarian cancer mortality by an estimated 20% after follow up of up to 14 years. Longer follow-up is needed to determine the ultimate mortality reduction and if screening the general population is cost effective.Read More
Abcodia has appointed Richard A. “Dick” Sandberg to its board of directors
Mr. Sandberg has played a principal role in founding and building a number of medical diagnostic companies. Previously he co-founded and served as chairman, CEO and president of DIANON Systems, Inc., a leading publicly traded provider of anatomic pathology and oncology testing services (acquired by LabCorp in 2003).Read More